

MAJOR INSURANCE MARKETS IN THE UNITED STATES

This infographic emphasizes the major insurance markets for branded drugs in the US.

There are other insurance markets (e.g., VA) that are not emphasized here.

COMMERCIAL MARKET



Includes employer-sponsored plans, private individual and family plans, and plans purchased through the Affordable Care Act (ACA) marketplace.



~55%
of Population



~36%
of Net Drug Spending

Financed by premiums paid for by the employer and/or beneficiary and taxes (for some ACA marketplace plans).

MEDICAID



Provides coverage for low-income adults, children, people with disabilities, and pregnant women.



~20%
of Population



~7%
of Net Drug Spending

Financed by a combination of federal and state taxes.

MEDICARE



Provides coverage for adults who are 65 years and older, people with disabilities, and people with specific conditions (e.g., end-stage renal disease).



~20%
of Population



~50%+
of Net Drug Spending

Financed by payroll taxes, general taxes, and premiums paid for by the beneficiary.



PART B
Drugs administered by a provider



PART D
Drugs dispensed by a pharmacy



We created this infographic based on the content discussed during the *Perspectives* podcast episode with Dr. Inma Hernandez. Listen to the full episode for a deeper dive.

BRANDED DRUG PRICING IN EACH MARKET

This infographic is a general overview of how the net price realized by the drug's innovator is established in each major US insurance market. Listen to the podcast episode to hear how 340B and a Maximum Fair Price factor into this.

INSURANCE MARKET



COMMERCIAL MARKET

HOW THE NET PRICE REALIZED BY THE INNOVATOR IS ESTABLISHED

The list price set by the innovator minus the rebates negotiated with the insurers for coverage and formulary placement.



MEDICAID

The list price set by the innovator minus the statutory rebate (combination of a base rebate and an inflation rebate) minus any state-level supplemental rebates. The base rebate is whichever is higher: 23% of the list price or the list price minus the lowest price offered in the commercial market.



MEDICARE

Part B: The Average Sales Price (ASP) minus any inflation rebates. The ASP is a volume-weighted average price that includes discounts, rebates, etc. to all purchasers.

Part D: The list price set by the innovator minus direct and indirect remuneration (e.g., negotiated rebates) minus an inflation rebate minus discounts from the manufacturer discount program (MDP). The MDP discount depends on the insurance plan benefit phase (e.g., deductible, initial, catastrophic).



We created this infographic based on the content discussed during the *Perspectives* podcast episode with Dr. Inma Hernandez. Listen to the full episode for a deeper dive.

AUTHOR:

Melanie D. Whittington,
Managing Director and Head
Leerink Center for Pharmacoeconomics

Disclosures

The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.

© 2026 MEDACorp LLC. All Rights Reserved.